Jonathan Walsh, MD

Alexander Hillel specializes in the medical and surgical management of patients who have scar tissue blocking their larynx and/or trachea, a condition called laryngotracheal stenosis. This condition occurs in patients who have had prolonged intubation, an autoimmune disease or a rare disease called idiopathic subglottic stenosis. He also treats patients with voice and throat problems, including spasmodic dysphonia and swallowing difficulty. After he earned his medical degree from the Tulane University School of Medicine, Dr. Hillel completed his residency in otolaryngology–head and neck surgery at the Johns Hopkins University School of Medicine and a fellowship in laryngology and airway surgery at the Emory Voice Center. Dr. Hillel directs a laboratory that seeks to better understand why scar forms in the larynx and trachea. In an effort to improve treatment, he and his team investigate the relationship between the immune system, bacteria and other antigens and scar formation in the airway. He has led a number of clinical trials to improve treatment for subglottic stenosis, including the first interventional study for idiopathic subglottic stenosis. Researchers in Dr. Hillel’s lab are also testing drugs that may halt the progression of, or reverse, scar formation, and they have engineered a drug-eluting stent that is being tested to translate to patients with subglottic stenosis. He holds sponsored grants to conduct his research from the National Institutes of Health, surgical foundations and the medical device industry. In addition to clinical and research work, Dr. Hillel has a leadership role within the Department of Otolaryngology–Head and Neck Surgery, serving as the vice director of education.

Courtney L. Carver, Au.D., CCC-A., earned her doctorate in audiology from the University of Florida. Dr. Carver is trained in the field of audiology. She offers professional audiological services, including cochlear implant consultation, programming, and counseling in pediatric and adult populations.

Dr. Nirmish Singla is an Associate Professor of Urology and Oncology in the Brady Urological Institute at Johns Hopkins University, where he serves as the Director of Translational Research in Genitourinary Oncology. He is also the Director of the Kidney Cancer Program and co-directs the Upper Tract Urothelial Cancer (UTUC) Program as a founding member of the first-ever UTUC Multidisciplinary Clinic. He represents the Sidney Kimmel Comprehensive Cancer Center (SKCCC) on the National Comprehensive Cancer Network (NCCN) Testicular Cancer Guidelines Panel and helps lead the Testicular Cancer Program. He serves the Brady in a leadership capacity as Vice Chair and Physician Advisor for Quality, Safety, & Service; Faculty Senator for the Department of Urology; and as a core faculty member for the Hopkins Business of Health Initiative (HBHI).Dr. Singla received his undergraduate degree (B.S.E.) in Biomedical Engineering from the University of Michigan and his medical degree (M.D.) from the University of Michigan Medical School, where he was supported by a full-tuition Dean’s Merit Scholarship. He went on to complete his residency training in Urologic Surgery at the University of Texas Southwestern Medical Center (UTSW). Following his residency, he received an NIH/NCI Ruth L. Kirschstein National Research Service Award T32 grant and spent an additional year at UTSW as a postdoctoral research fellow in Urologic Oncology with a specialized translational focus in kidney cancer through the Physician Scientist Training Program. During this time, he earned a Master of Science in Clinical Science (M.S.C.S.) degree through the Center for Translational Medicine at UTSW and helped develop and pioneer a Physician Administrative Fellowship program. He then completed an advanced surgical fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York through the Society of Urologic Oncology (SUO) before joining the faculty at Johns Hopkins.Dr. Singla’s clinical practice spans the complete spectrum of genitourinary oncology, including adrenal, kidney, upper tract, bladder, prostate, penile, urethral, and testicular cancers. His surgical approaches include mastery of both open and minimally-invasive (endoscopic, laparoscopic, and robotic) techniques. Dr. Singla provides personalized and compassionate care for patients affected by urologic cancer by integrating cutting-edge technologies and multidisciplinary approaches to treatment.As both a surgeon-scientist and clinical trialist, Dr. Singla’s overarching goal is to help scientific discoveries in the laboratory materialize for patients with urologic cancers in the clinic. He runs a well-funded, multidisciplinary, translational laboratory specializing in kidney cancer, testicular cancer, and UTUC. Dr. Singla has co-authored over 200 articles and textbook chapters, and he has developed an international reputation as a thought leader in urologic oncology. He has secured a substantial amount of research funding and serves as the lead PI on multiple grants from federal, foundational, intramural, and private sources across various GU malignancies.